Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erbstatin
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
**Erbstatin** is a synthetic *tyrosine kinase inhibitor* originally identified as a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase activity. It is typically used for research purposes rather than as a marketed pharmaceutical. Erbstatin blocks EGFR autophosphorylation and associated downstream signaling, thereby interfering with cellular proliferation and survival signals. Its primary applications are in cellular and biochemical studies investigating EGFR signaling pathways, cancer biology, and tyrosine kinase mechanisms.
- Other names
- erbstatin
02
Targets
TOP1 (DNA Topoisomerase I)TOP2A (DNA topoisomerase II)ERBB2 (Erb-b2 receptor tyrosine kinase 2)SFK (SRC family kinases)PKA (Cyclic amp-dependent protein kinase)
Beyond the preview
Go deeper on erbstatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erbstatin.